Leerink Swann Raises Price Target on Regeneron (REGN) to $182
Tweet Send to a FriendGet Alerts REGN Hot Sheet
Price: $258.07 -1.66%
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 23 | New: 29
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 23 | New: 29
Trade REGN Now!
Leerink Swann reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $182.00 (from $150.00).
MEDACorp conducted a survey of 50 U.S.ophthalmologists and based on the results analyst at Leerink Swan created a revenue model that suggests to that Eylea can continue to meet or beat street revenue estimates this year and next.
"Surveyed physicians still project a big step up in Eylea wet AMD market penetration over the next year. Treatment experienced patient penetration is expected to rise from 20.5% currently to 29% in one year and 33% in two years. Treatment naïve patient penetration is expected to rise from 17.5% currently to 26.6% in one year and 31.8% in two years,” said analyst Joseph P. Schwartz.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $158.24 yesterday, with a 52 week range of $49.58-$166.39.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
MEDACorp conducted a survey of 50 U.S.ophthalmologists and based on the results analyst at Leerink Swan created a revenue model that suggests to that Eylea can continue to meet or beat street revenue estimates this year and next.
"Surveyed physicians still project a big step up in Eylea wet AMD market penetration over the next year. Treatment experienced patient penetration is expected to rise from 20.5% currently to 29% in one year and 33% in two years. Treatment naïve patient penetration is expected to rise from 17.5% currently to 26.6% in one year and 31.8% in two years,” said analyst Joseph P. Schwartz.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $158.24 yesterday, with a 52 week range of $49.58-$166.39.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Compuware (CPWR) Estimates Trimmed, PT Raised at Jefferies
- Notable HP (HPQ) Bear Speaks, Says 'Recovery Unsustainable'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
